"Promising Activity" Of Cetuximab In Patients With Advanced Biliary Cancer
BARCELONA, SPAIN—Adding cetuximab to gemcitabine/oxaliplatin (GEMOX) chemotherapy controlled disease among two thirds of patients with advanced biliary cancer in a trial reported at the World Congress on Gastrointestinal Cancer. Éveline Boucher from the Centre Eugene Marquis, in Rennes, France, presented preliminary findings from a phase II open-label study among 101 patients who had not already received palliative treatment for their advanced biliary cancers, and had WHO performance status 0-1.
She discussed her team’s findings with Peter Goodwin.
by Oncolgy Times & Audio Medica
The podcast Oncology Times Broadcast News is embedded on this page from an open RSS feed. All files, descriptions, artwork and other metadata from the RSS-feed is the property of the podcast owner and not affiliated with or validated by Podplay.